Value Proposition

Investors

The need for radically different agents in the fight against untreatable infections has never been greater. Given the typical attrition rate of drug development programmes it is clear that there are too few AMR innovations currently in development. The urgency of the situation is reflected in the emergence of government-level initiatives to incentivise innovators and to ensure that effective antibacterials are valued appropriately; and recent deals demonstrate that certain major pharmaceutical companies are seeking assets in this space.

COMMERCIAL PROSPECTS

A New Commercial Paradigm

The Subscription Model (led by the UK) provides tariffs for guaranteed annual fees payable to the innovator of any new approved antimicrobial treatment which is made available to the National Health Service (NHS).

CHANGING HISTORICALLY POOR ROI

Driving Innovation Value

The commercial landscape for antibiotics is changing dramatically. International governmental and multinational corporate interest are creating a more remunerative environment, promising much-improved ROI.

Value Proposition

Our Value Proposition

MetalloBio is a value growth investment focused on commercialising its antibiotic drug candidates post-Phase 2 trials, primarily through licensing, while remaining open to other opportunities like mergers and acquisitions.

Learn More

Are you interested in exploring investment opportunities with MetalloBio (MBX) as we develop groundbreaking solutions to combat antimicrobial resistance? Please fill out the contact form below, and our investor relations team will reach out to discuss how you can be part of our mission to revolutionize healthcare while achieving significant returns.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.